Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

Molecular Cancer Therapeutics

Volumn 5, Issue 3, 2006, Pages 723-731

  Tang, Ruoping ^a   Faussat, Anne Marie ^a   Majdak, Patricia ^a   Marzac, Christophe ^a   Dubrulle, Sabine ^a   Marjanovic, Zora ^b   Legrand, Ollivier ^a   Marie, Jean Pierre ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CYCLOHEXIMIDE; CYTARABINE; CYTOCHROME C; DAUNORUBICIN; HOMOHARRINGTONINE; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; ENZYME RELEASE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS INHIBITION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CYTARABINE; CYTOCHROMES A; CYTOCHROMES C; DAUNORUBICIN; DOWN-REGULATION; HARRINGTONINES; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEMBRANE POTENTIALS; MITOCHONDRIA; NEOPLASM PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33645471372     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0164     Document Type: Article

References (23)

1. Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 2001;15:567-74.
2. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via up-regulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 2004;76:199-204.
3. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia. Blood 1999;93:4149-53.
4. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-α, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003;98:888-93.
5. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6:1185-8.
6. Robin JP, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomohar-ringtonine from a preformed chiral acyl moiety. Tetrahedron Letters 1999; 40:2931-4.
7. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer 2005;103:1850-5.
8. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607.
9. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett 2000;466:6-10.
10. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
11. Don AS, Hogg PJ. Mitochondria as cancer drug targets [review]. Trends Mol Med 2004;10:372-8.
12. Legrand O, Simonin G, Perrot JY, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998;9:4480-8.
13. Tang R, Faussat AM, Majdak P, et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 2004;18:1246-51.
14. Olmo N, Turnay J, Gonzalez de Buitrago G, et al. Cytotoxic mechanism of the ribotoxin α-sarcin induction of cell death via apoptosis. Eur J Biochem 2001;268:2113-23.
15. Sentenac S, Vekhoff A, Bardin C, et al. Phase I-II pharmacokinetic study of subcutaneous semi-synthetic homoharringtonine (HHT; MyelostatTM) in induction treatment of relapsing/refractory myeloid leukemia: an interim assessment. Blood 2003;102:232b (Abstract 4654).
16. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993;90: 3516-20.
17. Michels J, Johnson PW, Packham G. Mcl-1. Int J Biochem Cell Biol 2005;37:267-71.
18. Andersson Y, Juell S, Fodstad O. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin. Int J Cancer 2004;112:475-83.
19. Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem 2004;279:26915-21.
20. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability [review]. Cell Death Differ 2000;7:1182-9.
21. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
22. Moulding DA, Giles RV, Spiller DG, White MR, Tidd DM, Edwards SW. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 2000;96:1756-63.
23. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9.